| Market Cap | 445.39M | P/E | - | EPS this Y | 5.10% | Ern Qtrly Grth | - |
| Income | -113.58M | Forward P/E | -6.91 | EPS next Y | 14.20% | 50D Avg Chg | 65.00% |
| Sales | 85.01M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 87.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -21.00% |
| Recommedations | 1.70 | Quick Ratio | 7.55 | Shares Outstanding | 42.11M | 52W Low Chg | 176.00% |
| Insider Own | 9.20% | ROA | -26.24% | Shares Float | 24.44M | Beta | 1.13 |
| Inst Own | 93.39% | ROE | - | Shares Shorted/Prior | 6.37M/6.49M | Price | 18.99 |
| Gross Margin | 89.87% | Profit Margin | -133.61% | Avg. Volume | 543,385 | Target Price | 43.10 |
| Oper. Margin | -118.27% | Earnings Date | Nov 12 | Volume | 1,005,132 | Change | -6.45% |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Smith Jason Drew | General Counsel General Counsel | Jan 31 | Sell | 15.78 | 4,993 | 78,790 | 23,414 | 02/05/24 |
| Schoenberg Mark | Chief Medical Office.. Chief Medical Officer | Jan 31 | Sell | 15.78 | 3,789 | 59,790 | 151,437 | 02/05/24 |
| Nussbaum Ran | Director Director | Jun 06 | Option | 5 | 1,030 | 5,150 | 1,434,958 | 02/28/23 |
| Nussbaum Ran | Director Director | Oct 21 | Option | 5.94 | 47,999 | 285,114 | 1,485,168 | 02/28/23 |
| Nussbaum Ran | Director Director | Jun 16 | Option | 5 | 2,211 | 11,055 | 1,437,169 | 02/28/23 |
| Schoenberg Mark | Chief Medical Office.. Chief Medical Officer | Jan 20 | Option | 5 | 122,677 | 613,385 | 146,627 | 01/23/23 |
| Belldegrun Arie | Director Director | Sep 14 | Option | 5 | 160,000 | 800,000 | 408,693 | 09/16/22 |
| Belldegrun Arie | Director Director | Aug 31 | Option | 5 | 3,241 | 16,205 | 248,693 | 09/02/22 |
| Smith Jason Drew | General Counsel General Counsel | Aug 31 | Sell | 7.21 | 3,606 | 25,999 | 12,176 | 09/02/22 |
| Schoenberg Mark | Chief Medical Office.. Chief Medical Officer | Apr 30 | Sell | 6.62 | 254 | 1,681 | 23,467 | 05/03/22 |
| Smith Jason Drew | General Counsel General Counsel | Jan 31 | Sell | 7.58 | 414 | 3,138 | 7,449 | 02/02/22 |
| Barrett Elizabeth A. | Chief Executive Offi.. Chief Executive Officer | Jan 03 | Sell | 9.15 | 46,968 | 429,757 | 298,220 | 01/07/22 |